Онкогематология (Nov 2022)

Comparison of efficacy and toxicity of FC and FCR regimens in primary B-cell chronic lymphocytic leukemia: a retrospective study

  • Ye. А. Stadnik,
  • Ye. А. Nikitin,
  • B. V. Biderman,
  • G. N. Salogub,
  • Yu. Yu. Lorie,
  • N. N. Tsyba,
  • Yu. A. Alexeeva,
  • V. A. Doronin,
  • V. N. Mashuk,
  • R. I. Vabishevich,
  • A. L. Melikyan,
  • T. I. Kolosheinova,
  • L. Yu. Kolosova,
  • A. B. Sudarikov,
  • L. G. Kovaleva,
  • A. Yu. Zaritsky

DOI
https://doi.org/10.17650/1818-8346-2008-0-1-2-39-46
Journal volume & issue
Vol. 0, no. 1-2
pp. 39 – 46

Abstract

Read online

Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin. Comparison of efficacy of FC with FCR regimens administered in first line therapy and their influence on disease-free and overall survival in patients with B-cell lymphocytic leukemia were the main goals of this retrospective study. It has been demonstrated that inclusion of Rituximab into the FC regimen improves outcome of patients with B-cell lymphocytic leukemia without significant increase of toxicity.